RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.
BörsenkürzelRXST
Name des UnternehmensRxsight Inc
IPO-datumJul 30, 2021
CEODr. Ron M. Kurtz, M.D.
Anzahl der mitarbeiter498
WertpapierartOrdinary Share
GeschäftsjahresendeJul 30
Addresse100 Columbia Street
StadtALISO VIEJO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl92656
Telefon19495217822
Websitehttps://www.rxsight.com/
BörsenkürzelRXST
IPO-datumJul 30, 2021
CEODr. Ron M. Kurtz, M.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten